Nanotheranostic approaches for management of bloodstream bacterial infections

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 13, Issue 1, 2017, Pages 329-341

  Jagtap, Pramod ^a   Sritharan, Venkataraman ^b   Gupta, Shalini ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY DELHI   (India)

^b Global Medical Education and Research Foundation   (India)

Author keywords

Antibiotics; diagnosis; nanomaterial; pathogen; theranosis; therapy

Indexed keywords

ANTIBIOTICS; BIOMEDICAL ENGINEERING; DECISION MAKING; DIAGNOSIS; NANOSTRUCTURED MATERIALS; PATHOGENS; TURNAROUND TIME;

ANTIMICROBIAL RESISTANCES; BACTERIAL INFECTIONS; EARLY INTERVENTION; GLOBAL PUBLIC HEALTH; MEDICAL TECHNOLOGIES; NOVEL STRATEGIES; THERANOSIS; THERAPY;

HEALTH RISKS;

ANTIBIOTIC AGENT; BIOPOLYMER; GOLD NANOPARTICLE; LIGAND; MAGNETIC NANOPARTICLE; NANOCARRIER; NANOCOMPOSITE; NANOMATERIAL; NANOPARTICLE; SILICA NANOPARTICLE;

BACTERIAL INFECTION; BLOODSTREAM INFECTION; DEVICES; DRUG DELIVERY SYSTEM; HUMAN; LABORATORY DIAGNOSIS; MICROORGANISM DETECTION; NONHUMAN; PERSONALIZED MEDICINE; REVIEW; THERANOSTIC NANOMEDICINE; BACTERIAL INFECTIONS; BLOOD; CHEMISTRY; MICROBIOLOGY; SEPSIS;

BACTERIAL INFECTIONS; DRUG DELIVERY SYSTEMS; HUMANS; NANOSTRUCTURES; SEPSIS; THERANOSTIC NANOMEDICINE;

EID: 84997112307     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2016.09.005     Document Type: Review

References (129)

1. 1 Hall, M.J., Williams, S.N., DeFrances, C.J., Golosinskiy, A., Inpatient care for septicemia or sepsis: a challenge for patients and hospitals. NCHS Data Brief 62 (2011), 1–8.
2. 2 Gilham, I., Theranostics: an emerging tool in drug discovery and commercialisation. Drug Discov World, 2002.
3. 3 Phillips, M.A., Gran, M.L., Peppas, N.A., Targeted nanodelivery of drugs and diagnostics. Nano Today 5:2 (2010), 143–159.
4. 4 Cabral, H., Nishiyama, N., Kataoka, K., Supramolecular nanodevices: from design validation to theranostic nanomedicine. Acc Chem Res 44:10 (2011), 999–1008.
5. 5 Subbiah, R., Veerapandian, M., Yun, K.S., Nanoparticles: functionalization and multifunctional applications in biomedical sciences. Curr Med Chem 17 (2010), 4559–4577.
6. 6 Mura, S., Nicolas, J., Couvreur, P., Stimuli-responsive nanocarriers for drug delivery. Nat Mater 12:11 (2013), 991–1003.
7. 7 Wu, Z., Esteban-Fernández de Ávila, B., Martín, A., et al. RBC micromotors carrying multiple cargos towards potential theranostic applications. Nanoscale 7:32 (2015), 13680–13686.
8. 8 Lammers, T., Aime, S., Hennink, W.E., Storm, G., Kiessling, F., Theranostic nanomedicine. Acc Chem Res 44:10 (2011), 1029–1038.
9. 9 Cole, J.T., Holland, N.B., Multifunctional nanoparticles for use in theranostic applications. Drug Deliv Transl Res 5:3 (2015), 295–309.
10. 10 Kievit, F.M., Zhang, M., Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. Adv Mater 23:36 (2011), H217–H247.
11. 11 Diou, O., Tsapis, N., Fattal, E., Targeted nanotheranostics for personalized cancer therapy. Expert Opin Drug Deliv 9:12 (2012), 1475–1487.
12. 12 Subramanian, A., Manigandan, A., Sivashankari, P.R., Sethuraman, S., Development of nanotheranostics against metastatic breast cancer – a focus on the biology & mechanistic approaches. Biotechnol Adv 33:8 (2015), 1897–1911.
13. 13 Melancon, M.P., Stafford, R.J., Li, C., Challenges to effective cancer nanotheranostics. J Control Release 164:2 (2012), 177–182.
14. 14 Rosenblatt, J.E., Tropical infectious diseases: principles, pathogens, & practice. Mayo Clin Proc, 75(4), 2000, 426.
15. 15 Basu, M., Seggerson, S., Henshaw, J., Jiang, J., Del, A., Cordona, R., et al. Nano-biosensor development for bacterial detection during human kidney infection: use of nanowire arrays (GNWA). Scan Electron Microsc 21:8–9 (2004), 487–496.
16. 16 Boutayeb, A., The double burden of communicable and non-communicable diseases in developing countries. Trans R Soc Trop Med Hyg 100:3 (2006), 191–199.
17. 17 Khabbaz, R.F., Moseley, R.R., Steiner, R.J., Levitt, A.M., Bell, B.P., Challenges of infectious diseases in the USA. Lancet 384:9937 (2014), 53–63.
18. 18 Angus, D.C., van der Poll, T., Severe sepsis and septic shock. N Engl J Med 369 (2013), 840–851.
19. 19 Coelho, E.A.F., Chávez-Fumagalli, M.A., Costa, L.E., Tavares, C.A.P., Soto, M., Goulart, L.R., Theranostic applications of phage display to control leishmaniasis: selection of biomarkers for serodiagnostics, vaccination, and immunotherapy. Rev Soc Bras Med Trop 48:4 (2015), 370–379.
20. 20 Draz, M.S., Fang, B.A., Zhang, P., Hu, Z., Gu, S., Weng, K.C., et al. Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections. Theranostics 4:9 (2014), 872–892.
21. 21 Wain, J., Diep, T.S., Ho, V.A., Walsh, A.M., Hoa, N.T.T., Parry, C.M., et al. Quantitation of bacteria in blood of typhoid fever patients and relationship between counts and clinical features, transmissibility, and antibiotic resistance. J Clin Microbiol 36:6 (1998), 1683–1687.
22. 22 Wain, J., Bay, P.V.B., Vinh, H., Duong, N.M., Diep, T.S., Walsh, A.L., et al. Quantitation of bacteria in bone marrow from patients with typhoid fever: relationship between counts and clinical features. J Clin Microbiol 39:4 (2001), 1571–1576.
23. 23 Yu, M., Stott, S., Toner, M., Maheswaran, S., Haber, D.A., Circulating tumor cells: approaches to isolation and characterization. J Cell Biol 192:3 (2011), 373–382.
24. 24 Allard, W.J., Matera, J., Miller, M.C., Repollet, M., Connelly, M.C., Rao, C., et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10:20 (2004), 6897–6904.
25. 25 Houpikian, P., Raoult, D., Traditional and molecular techniques for the study of emerging bacterial diseases: one laboratory's perspective. Emerg Infect Dis 8:2 (2002), 122–131.
26. 26 Wang, Y., Guo, G., Wang, H., Yang, X., Shao, F., Yang, C., et al. Comparative study of bacteriological culture and real-time fluorescence quantitative PCR (RT-PCR) and multiplex PCR-based reverse line blot (mPCR/RLB) hybridization assay in the diagnosis of bacterial neonatal meningitis. BMC Pediatr 14 (2014), 1–8, 224.
27. 27 Chiba, N., Murayama, S.Y., Morozumi, M., Nakayama, E., Okada, T., Iwata, S., et al. Rapid detection of eight causative pathogens for the diagnosis of bacterial meningitis by real-time PCR. J Infect Chemother 15:2 (2009), 92–98.
28. 28 Yamamoto, Y., PCR in diagnosis of infection: detection of bacteria in cerebrospinal fluids. Clin Diagn Lab Immunol 9:3 (2002), 508–514.
29. 29 Mancini, N., Carletti, S., Ghidoli, N., Cichero, P., Burioni, R., Clementi, M., The era of molecular and other non-culture-based methods in diagnosis of sepsis. Clin Microbiol Rev 23:1 (2010), 235–251.
30. 30 Kumarasamy, V., Wahab, A.H.A., Chua, S.K., Hassan, Z., Chem, Y.K., Mohamad, M., et al. Evaluation of a commercial dengue NS1 antigen-capture ELISA for laboratory diagnosis of acute dengue virus infection. J Virol Methods 140:1–2 (2007), 75–79.
31. 31 Leibovici, L., Shraga, I., Drucker, M., Konigsberger, H., Samra, Z., Pitlik, S.D., The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 244:5 (1998), 379–386.
32. 32 Paul, M., Kariv, G., Goldberg, E., Raskin, M., Shaked, H., Hazzan, R., et al. Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 65:12 (2010), 2658–2665.
33. 33 Tangden, T., Combination antibiotic therapy for multidrug-resistant Gram-negative bacteria. Ups J Med Sci 119:2 (2014), 149–153.
34. 34 Ahmed, A., Rushworth, J.V., Hirst, N.A., Millner, P.A., Biosensors for whole-cell bacterial detection. Clin Microbiol Rev 27:3 (2014), 631–646.
35. 35 Ma, X., Zhao, Y., Liang, X.J., Theranostic nanoparticles engineered for clinic and pharmaceutics. Acc Chem Res 44:10 (2011), 1114–1122.
36. 36 de Villiers, M.M., Aramwit, P., Kwon, G.S., Nanotechnology in drug delivery. 2009, Springer, USA, 3–278.
37. 37 Benet, L.Z., Effect of route of administration and distribution on drug action. J Pharmacokinet Biopharm 6:6 (1978), 559–585.
38. 38 Sastry, S., Sastry, S., Nyshadham, J., Nyshadham, J., Fix, J., Fix, J., Recent technological advances in oral drug delivery – a review. Pharm Sci Technol Today 3:4 (2000), 138–145.
39. 39 Zhang, L., Pornpattananangku, D., Hu, C.-M.J., Huang, C.-M., Development of nanoparticles for antimicrobial drug delivery. Curr Med Chem 17:6 (2010), 585–594.
40. 40 Xie, S., Tao, Y., Pan, Y., Qu, W., Cheng, G., Huang, L., et al. Biodegradable nanoparticles for intracellular delivery of antimicrobial agents. J Control Release 187 (2014), 101–117.
41. 41 Kelly, C., Jefferies, C., Cryan, S.-A., Targeted liposomal drug delivery to monocytes and macrophages. J Drug Deliv 2011 (2011), 1–11.
42. 42 Singh, R., Lillard, J.W., Nanoparticle-based targeted drug delivery. Exp Mol Pathol 86:3 (2009), 215–223.
43. 43 Caldorera-Moore, M.E., Liechty, W.B., Peppas, N.A., Responsive theranostic systems: integration of diagnostic imaging agents and responsive controlled release drug delivery carriers. Acc Chem Res 44:10 (2011), 1061–1070.
44. 44 Tiwari, G., Tiwari, R., Sriwastawa, B., Bhati, L., Pandey, S., Pandey, P., et al. Drug delivery systems: an updated review. Int J Pharm Investig 2:1 (2012), 2–11.
45. 45 Rai, M., Ingle, A.P., Birla, S., Yadav, A., Santos, C.A., Strategic role of selected noble metal nanoparticles in medicine. Crit Rev Microbiol 42:5 (2015), 1–24.
46. 46 Kumar Khanna, V., Targeted delivery of nanomedicines. ISRN Pharmacol 2012 (2012), 1–9.
47. 47 Prabhu, R.H., Patravale, V.B., Joshi, M.D., Polymeric nanoparticles for targeted treatment in oncology: current insights. Int J Nanomedicine 10 (2015), 1001–1018.
48. 48 Al-Jamal, W.T., Kostarelos, K., Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Acc Chem Res 44:10 (2011), 1094–1104.
49. 49 Fahmy, T.M., Fong, P.M., Goyal, A., Saltzman, W.M., Targeted for drug delivery. Mater Today 8 (2005), 18–26.
50. 50 Gao, W., Thamphiwatana, S., Angsantikul, P., Zhang, L., Nanoparticle approaches against bacterial infections. Wiley Interdiscip Rev Nanomed Nanobiotechnol 6:6 (2014), 532–547.
51. 51 Allouche, J., Synthesis of organic and bioorganic nanoparticles: an overview of the preparation methods. Brayner, R., Fiévet, F., Coradin, T., (eds.) Nanomaterials: a danger or a promise?: A chemical and biological perspective, 1st ed., 2013, Springer-Verlag, London, 27–74.
52. 52 Hosseini, S., Ibrahim, F., Djordjevic, I., Koole, L.H., Polymethyl methacrylate-co-methacrylic acid coatings with controllable concentration of surface carboxyl groups: a novel approach in fabrication of polymeric platforms for potential bio-diagnostic devices. Appl Surf Sci 300 (2014), 43–50.
53. 53 Zhao, Y., Zhao, X., Hu, J., Xu, M., Zhao, W., Sun, L., et al. Encoded porous beads for label-free multiplex detection of tumor markers. Adv Mater 21:5 (2009), 569–572.
54. 54 Wilson, J.N., Wang, Y., Lavigne, J.J., Bunz, U.H., A biosensing model system: selective interaction of biotinylated PPEs with streptavidin-coated polystyrene microspheres. Chem Commun 1:14 (2003), 1626–1627.
55. 55 Li, J., Cai, P., Shalviri, A., Henderson, J.T., He, C., Foltz, W.D., et al. A multifunctional polymeric nanotheranostic system delivers doxorubicin and imaging agents across the blood–brain barrier targeting brain metastases of breast cancer. ACS Nano 8:10 (2014), 9925–9940.
56. 56 Cho, H., Kwon, G.S., Polymeric micelles for neoadjuvant cancer therapy and tumor-primed optical imaging. ACS Nano 5:11 (2011), 8721–8729.
57. 57 Feracci, H., Gutierrez, B.S., Hempel, W., Gil, I.S., Organic nanoparticles. Front Nanosci 4:1 (2012), 197–230.
58. 58 Zafar, N., Fessi, H., Elaissari, A., Colloidal particles containing labeling agents and cyclodextrins for theranostic applications. Int J Pharm 472:1–2 (2014), 118–129.
59. 59 Shen, J., Kim, H.C., Su, H., Wang, F., Wolfram, J., Kirui, D., et al. Cyclodextrin and polyethylenimine functionalized mesoporous silica nanoparticles for delivery of siRNA cancer therapeutics. Theranostics 4:5 (2014), 487–497.
60. 60 Shityakov, S., Salmas, R.E., Salvador, E., Roewer, N., Evaluation of the potential toxicity of unmodified and modified cyclodextrins on murine blood–brain barrier endothelial cells., 41(2), 2016, 175–184.
61. 61 Wang, L.S., Chuang, M.C., Ho, J.A., Nanotheranostics – a review of recent publications. Int J Nanomedicine 7 (2012), 4679–4695.
62. 62 Bardhan, N.M., Ghosh, D., Belcher, A.M., Carbon nanotubes as in vivo bacterial probes. Nat Commun 5 (2014), 1–11, 4918.
63. 63 Shityakov, S., Salvador, E., Pastorin, G., Förster, C., Blood–brain barrier transport studies, aggregation, and molecular dynamics simulation of multiwalled carbon nanotube functionalized with fluorescein isothiocyanate. Int J Nanomedicine 10 (2015), 1703–1713.
64. 64 Bangal, M., Ashtaputre, S., Marathe, S., Ethiraj, A., Hebalkar, N., Gosavi, S.W., et al. Semiconductor nanoparticles. Hyperfine Interact 160:1–4 (2005), 81–94.
65. 65 Smith, A.M., Nie, S., Semiconductor nanocrystals: structure, properties, and band gap engineering. Acc Chem Res 43:2 (2010), 190–200.
66. 66 Venkat Kumar, G., Su, C.H., Velusamy, P., Surface immobilization of kanamycin-chitosan nanoparticles on polyurethane ureteral stents to prevent bacterial adhesion. Biofouling 32:8 (2016), 861–870.
67. 67 Syed, M.A., Bokhari, S.H.A., Gold nanoparticle based microbial detection and identification. J Biomed Nanotechnol 7:2 (2011), 229–237.
68. 68 Tiwari, P.M., Vig, K., Dennis, V.A., Singh, S.R., Functionalized gold nanoparticles and their biomedical applications. Nanomaterials 1 (2011), 31–63.
69. 69 Hirlekar, R., Jagtap, P., Kadam, V., Advanced vectors for gene delivery. Curr Drug Ther 6 (2011), 251–262.
70. 70 Chinen, A.B., Guan, C.M., Ferrer, J.R., Barnaby, S.N., Merkel, T.J., Mirkin, C.A., Nanoparticle probes for the detection of cancer biomarkers, cells, and tissues by fluorescence. Chem Rev 115:19 (2015), 10530–10574.
71. 71 Ajnai, G., Chiu, A., Tzuchun, K., Chun-Chia, C., Teh-Hua, T., Jungshan, C., Trends of gold nanoparticle-based drug delivery system in cancer therapy. J Exp Clin Med 6:6 (2014), 172–178.
72. 72 Ghosh, P., Han, G., De, M., Kim, C.K., Rotello, V.M., Gold nanoparticles in delivery applications. Adv Drug Deliv Rev 60:11 (2008), 1307–1315.
73. 73 Yoo, D., Lee, J.H., Shin, T.H., Cheon, J., Theranostic magnetic nanoparticles. Acc Chem Res 44:10 (2011), 863–874.
74. 74 Pfaller, M.A., Wolk, D.M., Lowery, T.J., T2MR and T2Candida: novel technology for the rapid diagnosis of candidemia and invasive candidiasis. Future Microbiol 11 (2016), 103–117.
75. 75 Jokerst, J.V., Gambhir, S.S., Molecular imaging with theranostic nanoparticles. Acc Chem Res 44:10 (2011), 1050–1060.
76. 76 Wabler, M., Zhu, W., Hedayati, M., Attaluri, A., Zhou, H., Mihalic, J., et al. Magnetic resonance imaging contrast of iron oxide nanoparticles developed for hyperthermia is dominated by iron content. Int J Hyperthermia 30:3 (2014), 192–200.
77. 77 Chung, H.J., Castro, C.M., Im, H., Lee, H., Weissleder, R., A magneto-DNA nanoparticle system for rapid detection and phenotyping of bacteria. Nat Nanotechnol 8:5 (2013), 369–375.
78. 78 Neuberger, T., Schöpf, B., Hofmann, H., Hofmann, M., Von Rechenberg, B., Superparamagnetic nanoparticles for biomedical applications: Possibilities and limitations of a new drug delivery system. J Magn Magn Mater 293 (2005), 483–496.
79. 79 Ambrogio, M.W., Thomas, C.R., Zhao, Y.L., Zink, J.I., Stoddart, J.F., Mechanized silica nanoparticles: a new frontier in theranostic nanomedicine. Acc Chem Res 44:10 (2011), 903–913.
80. 80 Lee, J.E., Lee, N., Kim, T., Kim, J., Hyeon, T., Multifunctional mesoporous silica nanocomposite nanoparticles for theranostic applications. Acc Chem Res 44:10 (2011), 893–902.
81. 81 Lee, J.E., Lee, N., Kim, H., Kim, J., Choi, S.H., Kim, J.H., et al. Uniform mesoporous dye-doped silica nanoparticles decorated with multiple magnetite nanocrystals for simultaneous enhanced magnetic resonance imaging, fluorescence imaging, and drug delivery. J Am Chem Soc 132:2 (2010), 552–557.
82. 82 Kuthati, Y., Sung, P.J., Weng, C.F., Mou, C.Y., Lee, C.H., Functionalization of mesoporous silica nanoparticles for targeting, biocompatibility, combined cancer therapies and theragnosis. J Nanosci Nanotechnol 13:4 (2013), 2399–2430.
83. 83 Wang, L., Zhao, W., O'Donoghue, M.B., Tan, W., Fluorescent nanoparticles for multiplexed bacteria monitoring. Bioconjug Chem 18:2 (2007), 297–301.
84. 84 Yong, K.T., Roy, I., Swihart, M.T., Prasad, P.N., Multifunctional nanoparticles as biocompatible targeted probes for human cancer diagnosis and therapy. J Mater Chem 19:27 (2009), 4655–4672.
85. 85 Loo, C., Lin, A., Hirsch, L., Lee, M.H., Barton, J., Halas, N., et al. Nanoshell-enabled photonics-based imaging and therapy of cancer. Technol Cancer Res Treat 3:1 (2004), 33–40.
86. 86 Ke, H., Yue, X., Wang, J., Xing, S., Zhang, Q., Dai, Z., et al. Gold nanoshelled liquid perfluorocarbon nanocapsules for combined dual modal ultrasound/ct imaging and photothermal therapy of cancer. Small 10:6 (2014), 1220–1227.
87. 87 Ke, H., Wang, J., Tong, S., Jin, Y., Wang, S., Qu, E., et al. Gold nanoshelled liquid perfluorocarbon magnetic nanocapsules: a nanotheranostic platform for bimodal ultrasound/magnetic resonance imaging guided photothermal tumor ablation. Theranostics 4:1 (2014), 12–23.
88. 88 Ke, H., Wang, J., Dai, Z., Jin, Y., Qu, E., Xing, Z., et al. Gold-nanoshelled microcapsules: a theranostic agent for ultrasound contrast imaging and photothermal therapy. Angew Chem Int Ed Engl 50:13 (2011), 3017–3021.
89. 89 TJ, Y., Li, P.H., Tseng, T.W., Chen, Y.C., Multifunctional Fe(3)O(4)/alumina core/shell MNPs as photothermal agents for targeted hyperthermia of nosocomial and antibiotic-resistant bacteria. Nanomedicine (Lond) 6:8 (2011), 1353–1363.
90. 90 Ferreira Soares, D.C., Theranostic nanoparticles: imaging and therapy combined. J Mol Pharm Org Process Res 2:1 (2014), 1–2.
91. 91 Souza-Fonseca-Guimaraes, F., Adib-Conquy, M., Cavaillon, J.-M., Natural killer (NK) cells in antibacterial innate immunity: angels or devils?. Mol Med 18 (2012), 270–285.
92. 92 Lewis, K., Programmed death in bacteria. Microbiol Mol Biol Rev 64:3 (2000), 503–514.
93. 93 Shimizu, T., Obata, T., Sonoda, H., et al. The ability of endotoxin adsorption during a longer duration of direct hemoperfusion with a polymyxin B-immobilized fiber column in patients with septic shock. Transfus Apher Sci 49:3 (2013), 499–503.
94. 94 Vincent, J.-L., Sakr, Y., Sprung, C.L., Ranieri, V.M., Reinhart, K., Gerlach, H., et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 34:2 (2006), 344–353.
95. 95 Herrmann, I.K., Urner, M., Graf, S., Schumacher, C.M., Roth-Z'graggen, B., Hasler, M., et al. Endotoxin removal by magnetic separation-based blood purification. Adv Healthc Mater 2:6 (2013), 829–835.
96. 96 Gu, H., Ho, P.L., Tsang, K.W.T., Wang, L., Xu, B., Using biofunctional magnetic nanoparticles to capture vancomycin-resistant enterococci and other Gram-positive bacteria at ultralow concentration. J Am Chem Soc 125:51 (2003), 15702–15703.
97. 97 Kalita, P., Dasgupta, A., Sritharan, V., Gupta, S., Nanoparticle-drug bioconjugate as dual functional affinity ligand for rapid point-of-care detection of endotoxin in water and serum. Anal Chem 87:21 (2015), 11007–11012.
98. 98 Liu, Z., Liu, J., Wang, R., Du, Y., Ren, J., Qu, X., An efficient nano-based theranostic system for multi-modal imaging-guided photothermal sterilization in gastrointestinal tract. Biomaterials 56 (2015), 206–218.
99. 99 Patel, S.K., Janjic, J.M., Macrophage targeted theranostics as personalized nanomedicine strategies for inflammatory diseases. Theranostics 5:2 (2015), 150–172.
100. 100 Gamella, M., Guz, N., Mailloux, S., Pingarrón, J.M., Katz, E., Antibacterial drug release electrochemically stimulated by the presence of bacterial cells – theranostic approach. Electroanalysis 26:12 (2014), 2552–2557.
101. 101 Thompson, M., Blaszykowski, C., Sheikh, S., Romaschin, A., A true theranostic approach to medicine: towards tandem sensor detection and removal of endotoxin in blood. Biosens Bioelectron 67 (2015), 3–10.
102. 102 DeGrasse, J.A., A single-stranded DNA aptamer that selectively binds to Staphylococcus aureus enterotoxin B. PLoS One 7:3 (2012), 1–7, e33410.
103. 103 Dai, X., Fan, Z., Lu, Y., Ray, P.C., Multifunctional nanoplatforms for targeted multidrug-resistant-bacteria theranostic applications. ACS Appl Mater Interfaces 5:21 (2013), 11348–11354.
104. 104 Kim, J.W., Galanzha, E.I., Zaharoff, D.A., Griffin, R.J., Zharov, V.P., Nanotheranostics of circulating tumor cells, infections and other pathological features in vivo. Mol Pharm 10:3 (2013), 813–830.
105. 105 Setyawati, M.I., Kutty, R.V., Tay, C.Y., Yuan, X., Xie, J., Leong, D.T., et al. Novel theranostic DNA nanoscaffolds for the simultaneous detection and killing of Escherichia coli and Staphylococcus aureus. ACS Appl Mater Interfaces 6:24 (2014), 21822–21831.
106. 106 Pei, H., Zuo, X., Zhu, D., Huang, Q., Fan, C., Functional DNA nanostructures for theranostic applications. Acc Chem Res 47:2 (2014), 550–559.
107. 107 Pini, A., Falciani, C., Mantengoli, E., Bindi, S., Brunetti, J., Iozzi, S., et al. A novel tetrabranched antimicrobial peptide that neutralizes bacterial lipopolysaccharide and prevents septic shock in vivo. FASEB J 24:4 (2010), 1015–1022.
108. 108 Zola, H., Health, C., Monoclonal Antibodies: Diagnostic Uses. 2001, Encyclopedia of Sciences, 1–9.
109. 109 Harris, M.C., Polin, R.A., The detection of streptococcal antigens using monoclonal antibodies. Clin Lab Med 5:3 (1985), 545–560.
110. 110 Shigdar, S., Macdonald, J., O'Connor, M., Wang, T., Xiang, D., Al Shamaileh, H., et al. Aptamers as theranostic agents: modifications, serum stability and functionalisation. Sensors (Basel) 13:10 (2013), 13624–13637.
111. 111 Abe, K., Yoshida, W., Ikebukuro, K., Electrochemical biosensors using aptamers for theranostics. Adv Biochem Eng Biotechnol 140 (2014), 183–202.
112. 112 Disney, M.D., Zheng, J., Swager, T.M., Seeberger, P.H., Detection of bacteria with carbohydrate-functionalized fluorescent polymers. J Am Chem Soc 126:41 (2004), 13343–13346.
113. 113 Rizzo, L.Y., Theek, B., Storm, G., Kiessling, F., Lammers, T., Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications. Curr Opin Biotechnol 24:6 (2013), 1159–1166.
114. 114 Bissonnette, L., Bergeron, M.G., Infectious disease management through point-of-care personalized medicine molecular diagnostic technologies. J Pers Med 2:2 (2012), 50–70.
115. 115 Lu, P.L., Chen, Y.C., Ou, T.W., Chen, H.H., Tsai, H.C., Wen, C.J., et al. Multifunctional hollow nanoparticles based on graft-diblock copolymers for doxorubicin delivery. Biomaterials 32:8 (2011), 2213–2221.
116. 116 Correia, A., Shahbazi, M.-A., Mäkilä, E., Almeida, S., Salonen, J., Hirvonen, J., et al. Cyclodextrin-modified porous silicon nanoparticles for efficient sustained drug delivery and proliferation inhibition of breast cancer cells. ACS Appl Mater Interfaces 7:41 (2015), 23197–23204.
117. 117 Bagalkot, V., Zhang, L., Levy-Nissenbaum, E., Jon, S., Kantoff, P.W., Langer, R., et al. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on Bi-fluorescence resonance energy transfer. Nano Lett 7 (2007), 3065–3070.
118. 118 Chen, W.H., Xu, X.D., Jia, H.Z., Lei, Q., Luo, G.F., Cheng, S.X., et al. Therapeutic nanomedicine based on dual-intelligent functionalized gold nanoparticles for cancer imaging and therapy in vivo. Biomaterials 34:34 (2013), 8798–8807.
119. 119 Gao, J.H., Li, L., Ho, P.L., Mak, G.C., Gu, H.W., Xu, B., Combining fluorescent probes and biofunctional magnetic nanoparticles for rapid detection of bacteria in human blood. Adv Mater 18 (2006), 3145–3148.
120. 120 Chen, L., Bioconjugated magnetic nanoparticles for rapid capture of Gram-positive bacteria. J Biosens Bioelectron 01:S11 (2012), 1–5.
121. 121 Menon, J.U., Jadeja, P., Tambe, P., Vu, K., Yuan, B., Nguyen, K.T., Nanomaterials for photo-based diagnostic and therapeutic applications. Theranostics 3:3 (2013), 152–166.
122. 122 Conde, J., Oliva, N., Artzi, N., Implantable hydrogel embedded dark-gold nanoswitch as a theranostic probe to sense and overcome cancer multidrug resistance. Proc Natl Acad Sci U S A 112:11 (2015), E1278–E1287.
123. 123 Lin, Y.-S., Tsai, P.-J., Weng, M.-F., Chen, Y.-C., Affinity capture using vancomycin-bound magnetic nanoparticles for the MALDI-MS analysis of bacteria. Anal Chem 77:6 (2005), 1753–1760.
124. 124 Chu, Y.W., Engebretson, D.A., Carey, J.R., Bioconjugated magnetic nanoparticles for the detection of bacteria. J Biomed Nanotechnol 9:12 (2013), 1951–1961.
125. 125 Picard, F.J., Bergeron, M.G., Rapid molecular theranostics in infectious diseases. Drug Discov Today 7:21 (2002), 1092–1101.
126. 126 Mitka, M., Hospitalizations for extreme conditions mean extreme expenses, Study Verifies., 304(23), 2011, 2579–2580.
127. 127 Ventola, C.L., The antibiotic resistance crisis: part 1: causes and threats. P T 40:4 (2015), 277–283.
128. 128 Wilson, C.O., Gisvold, O., Block, J.H., Antibacterial antibiotics. Beale, J.M., (eds.) Wilson and Gisvold's textbook of organic medicinal and pharmaceutical chemistry, 12th ed., 2011, Lippincott Williams & Wilkins, New York, 258–326.
129. 129 Velkov, T., Thompson, P.E., Nation, R.L., Li, J., Structure–activity relationships of polymyxin antibiotics. J Med Chem 53:5 (2010), 1898–1916.